Inhibrx Biosciences, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$1.44 | -$1.44 | -$1.44 |
| Q2 2024 | 1 | -$3.60 | -$3.60 | -$3.60 |
| Q3 2024 | 2 | -$3.70 | -$3.06 | -$3.38 |
| Q4 2024 | 1 | -$2.89 | -$2.89 | -$2.89 |
| Q1 2025 | 1 | -$2.06 | -$2.06 | -$2.06 |
| Q2 2025 | 1 | -$1.52 | -$1.52 | -$1.52 |
| Q3 2025 | 1 | -$1.55 | -$1.55 | -$1.55 |
| Q4 2025 | 1 | -$1.58 | -$1.58 | -$1.58 |
Inhibrx Biosciences, Inc. Earnings Date And Information
Inhibrx Biosciences, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-2.84 earnings per share for the quarter, topping analysts' consensus estimates of $-3.06 by $0.22. The company had revenue of 0 for the quarter and had revenue of 1.80 M for the year. Inhibrx Biosciences, Inc. has generated $-5 earnings per share over the last year ($-5.12 diluted earnings per share) and currently has a price-to-earnings ratio of 0.13. Inhibrx Biosciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based on prior year's report dates.
Inhibrx Biosciences, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$3.06 | -$2.84 | 0.22 | $50,000 | $0 |
| 08/13/2024 | Q2 2024 | -$3.60 | $128.35 | 131.95 | $50,000 | $100,000 |
| 05/09/2024 | Q1 2024 | -$1.44 | $0 | |||
| 02/28/2024 | Q4 2023 | -$1.07 | -$1.73 | -0.66 | $1.63 M | |
| 11/09/2023 | Q3 2023 | -$1.01 | -$1.10 | -0.09 | $119,000 | |
| 08/07/2023 | Q2 2023 | -$1.02 | -$1.08 | -0.06 | $30,000 | |
| 05/08/2023 | Q1 2023 | -$0.84 | -$1.12 | -0.28 | $17,000 | |
| 03/06/2023 | Q4 2022 | -$0.80 | -$0.95 | -0.15 | $274,000 | |
| 11/07/2022 | Q3 2022 | -$1.01 | -$1.04 | -0.03 | $633,333 | $278,000 |
| 08/08/2022 | Q2 2022 | -$0.84 | -$0.97 | -0.13 | $1.07 M | $711,000 |
| 05/09/2022 | Q1 2022 | -$0.62 | -$0.86 | -0.24 | $915,000 | |
| 02/28/2022 | Q4 2021 | -$0.53 | -$0.55 | -0.02 | $2.84 M | |
| 11/09/2021 | Q3 2021 | -$0.57 | -$0.54 | 0.03 | $1.00 M | $2.51 M |
| 08/09/2021 | Q2 2021 | -$0.51 | -$0.55 | -0.04 | $825,000 | $918,000 |
| 05/13/2021 | Q1 2021 | -$0.61 | -$0.51 | 0.1 | $863,000 | |
| 03/12/2021 | Q4 2020 | -$0.50 | -$0.47 | 0.03 | $2.78 M | |
| 11/13/2020 | Q3 2020 | -$0.60 | -$0.77 | -0.17 | $1.00 M | $5.83 M |
| 06/29/2020 | Q2 2020 | -$0.50 | $3.33 M | |||
| 03/30/2020 | Q1 2020 | -$0.70 | $872,000 | |||
| 12/30/2019 | Q4 2019 | -$0.57 | $267,000 |
Inhibrx Biosciences, Inc. Earnings: Frequently Asked Questions
-
When is Inhibrx Biosciences, Inc.'s earnings date?
Inhibrx Biosciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based off last year's report dates.
-
Did Inhibrx Biosciences, Inc. beat their earnings estimates last quarter?
In the previous quarter, Inhibrx Biosciences, Inc. (:INBX) reported $-2.84 earnings per share (EPS) to beat the analysts' consensus estimate of $-3.06 by $0.22.
-
How can I listen to Inhibrx Biosciences, Inc.'s earnings conference call?
The conference call for Inhibrx Biosciences, Inc.'s latest earnings report can be listened to online.
-
How can I read Inhibrx Biosciences, Inc.'s conference call transcript?
The conference call transcript for Inhibrx Biosciences, Inc.'s latest earnings report can be read online.
-
How much revenue does Inhibrx Biosciences, Inc. generate each year?
Inhibrx Biosciences, Inc. (:INBX) has a recorded annual revenue of $1.80 M.
-
How much profit does Inhibrx Biosciences, Inc. generate each year?
Inhibrx Biosciences, Inc. (:INBX) has a recorded net income of $1.80 M. Inhibrx Biosciences, Inc. has generated $-5.12 earnings per share over the last four quarters.
-
What is Inhibrx Biosciences, Inc.'s price-to-earnings ratio?
Inhibrx Biosciences, Inc. (:INBX) has a price-to-earnings ratio of 0.13 and price/earnings-to-growth ratio is -0.1.
